Acelyrin, Inc. (SLRN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acelyrin, Inc. (SLRN) with AI Score 45/100 (Weak). Acelyrin, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Acelyrin, Inc. (SLRN) Healthcare & Pipeline Overview
Acelyrin, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted therapeutics for inflammatory diseases. Their lead candidate, izokibep, aims to treat conditions like Hidradenitis Suppurativa and Psoriatic Arthritis. With a focus on high-potency IL-17A inhibition, Acelyrin seeks to address unmet needs in immunology.
What Is the Investment Thesis for SLRN?
Acelyrin's investment thesis centers on the potential of izokibep to address significant unmet needs in inflammatory diseases. The ongoing Phase 3 trials for HS, PsA, and uveitis represent near-term catalysts. Positive data from these trials could drive significant value. The company's focus on IL-17A inhibition, a validated target, reduces some development risk. However, the company's negative P/E ratio of -1.25 and high negative profit margin of -53463.5% indicate substantial ongoing R&D expenses and a lack of current profitability. Successful commercialization of izokibep and advancement of other pipeline assets are critical for long-term value creation. The company's market capitalization of $0.23 billion reflects both the potential and the risks associated with clinical-stage biopharmaceutical companies.
Based on FMP financials and quantitative analysis
SLRN Key Highlights
- Lead product candidate izokibep is in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, indicating advanced stage development.
- Developing lonigutamab, a humanized IgG1 monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
- SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, is in preclinical stage for use in the treatment of chronic urticaria, demonstrating pipeline expansion.
- Gross Margin of 19.0% indicates some revenue generation, though profitability is currently negative.
- Market Cap of $0.23B reflects investor valuation of the company's pipeline and potential.
Who Are SLRN's Competitors?
What Are SLRN's Key Strengths?
- Promising lead product candidate (izokibep) in Phase 3 trials.
- Focus on a validated drug target (IL-17A).
- Experienced management team with expertise in drug development.
- Strong intellectual property position.
What Are SLRN's Weaknesses?
- Limited revenue generation and high operating losses.
- Reliance on the success of izokibep.
- Competition from established players in the immunology market.
- Relatively small company size.
What Could Drive SLRN Stock Higher?
- Data readout from Phase 3 clinical trials of izokibep for Hidradenitis Suppurativa (HS) in Q4 2026.
- Data readout from Phase 3 clinical trials of izokibep for Psoriatic Arthritis (PsA) in Q1 2027.
- Initiation of Phase 3 clinical trials of izokibep for uveitis in Q2 2026.
- Enrollment and progress in Phase 2 clinical trials of izokibep for Axial Spondyloarthritis.
- Advancement of lonigutamab through Phase 1 clinical trials for thyroid eye disease.
What Are the Key Risks for SLRN?
- Clinical trial failures or delays for izokibep or other pipeline assets.
- Regulatory hurdles and potential rejection of marketing applications.
- Competition from established players and biosimilars.
- High cash burn rate and need for additional financing.
- Dependence on key personnel and potential loss of talent.
What Are the Growth Opportunities for SLRN?
- Growth opportunity 1: Successful completion and positive data readout from the ongoing Phase 3 clinical trials of izokibep for Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), and uveitis. These indications represent significant market opportunities, with the global HS market projected to reach billions of dollars. Positive results could lead to regulatory approvals and commercial launch, driving revenue growth. The timeline for data readout and potential approval is estimated within the next 1-2 years, offering a near-term catalyst.
- Growth opportunity 2: Expansion of izokibep's clinical development program into additional indications beyond the current Phase 3 trials. Exploring its potential in other IL-17A-mediated diseases could broaden its market reach and extend its lifecycle. This strategy could involve initiating new clinical trials in indications with unmet needs, potentially leveraging existing data and clinical experience. The timeline for this expansion is estimated within the next 2-3 years.
- Growth opportunity 3: Advancement of lonigutamab, the humanized IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), through clinical development for the treatment of thyroid eye disease (TED). Successful completion of Phase 1 trials and progression to later-stage development could unlock a significant market opportunity in TED. The timeline for this advancement is estimated within the next 3-5 years.
- Growth opportunity 4: Strategic acquisitions or licensing of additional pipeline assets to complement Acelyrin's existing portfolio. This could involve acquiring rights to promising preclinical or clinical-stage assets in immunology or related therapeutic areas. Such acquisitions could diversify the company's pipeline and reduce its reliance on izokibep. The timeline for potential acquisitions is ongoing, depending on available opportunities.
- Growth opportunity 5: Development and commercialization of SLRN-517, the fully human IgG1 monoclonal antibody targeting c-KIT, for the treatment of chronic urticaria. Successful completion of preclinical studies and progression into clinical trials could unlock a significant market opportunity in chronic urticaria. The timeline for this advancement is estimated within the next 4-6 years.
What Opportunities Does SLRN Have?
- Expansion of izokibep into additional indications.
- Strategic acquisitions or licensing of new pipeline assets.
- Partnerships with larger pharmaceutical companies.
- Advancements in drug delivery technologies.
What Threats Does SLRN Face?
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from biosimilars or generic drugs.
- Changes in healthcare reimbursement policies.
What Are SLRN's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Expertise in immunology and drug development.
- Strategic partnerships with leading researchers and institutions.
What Does SLRN Do?
Acelyrin, Inc., founded in 2020 and headquartered in Agoura Hills, California, is a clinical-stage biopharmaceutical company dedicated to identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's primary focus is on addressing unmet medical needs in the field of immunology. Acelyrin's lead product candidate, izokibep, is a small protein therapeutic engineered for high-potency inhibition of IL-17A. Izokibep is currently in Phase 3 clinical trials for the treatment of Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), and uveitis, as well as Phase 2 clinical trials for Axial Spondyloarthritis (axSpA). In addition to izokibep, Acelyrin is developing lonigutamab, a humanized IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), currently in Phase 1 clinical trials for thyroid eye disease (TED). The company's pipeline also includes SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, in the preclinical stage for the treatment of chronic urticaria. Acelyrin's strategy involves a combination of internal development and strategic acquisitions to expand its portfolio of innovative therapies. The company aims to improve the lives of patients suffering from a range of immune-mediated diseases.
What Products and Services Does SLRN Offer?
- Develops and commercializes transformative medicines.
- Focuses on identifying and acquiring promising drug candidates.
- Specializes in therapies for immune-mediated diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals for its products from health authorities.
- Aims to improve the lives of patients with inflammatory diseases.
How Does SLRN Make Money?
- Develops and patents novel therapeutic candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered products.
- Funds research and development through venture capital and public offerings.
What Industry Does SLRN Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like Acelyrin focused on developing novel therapies for unmet medical needs. The market for inflammatory disease treatments is substantial and growing, driven by an aging population and increasing prevalence of autoimmune disorders. Competition is intense, with established players and emerging biotechs vying for market share. Acelyrin's focus on IL-17A inhibition places it in a competitive landscape with companies developing similar mechanisms of action. Success depends on demonstrating superior efficacy, safety, and patient convenience.
Who Are SLRN's Key Customers?
- Patients suffering from Hidradenitis Suppurativa (HS).
- Patients suffering from Psoriatic Arthritis (PsA).
- Patients suffering from uveitis.
- Patients suffering from Axial Spondyloarthritis (axSpA).
- Patients suffering from thyroid eye disease (TED).
SLRN Financials
SLRN Latest News
-
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
benzinga · Jan 7, 2025
-
Earnings Scheduled For November 13, 2024
benzinga · Nov 13, 2024
-
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jul 8, 2024
-
Earnings Scheduled For November 7, 2023
benzinga · Nov 7, 2023
SLRN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLRN.
Price Targets
Wall Street price target analysis for SLRN.
SLRN MoonshotScore
What does this score mean?
The MoonshotScore rates SLRN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are SLRN's Competitors?
Latest News
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Earnings Scheduled For November 13, 2024
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Earnings Scheduled For November 7, 2023
Leadership: Mina Kim
CEO
Mina Kim is the Chief Executive Officer of Acelyrin, Inc. Her background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. She has held leadership positions at various companies, contributing to the development and launch of multiple successful products. Her expertise spans across various therapeutic areas, including immunology and oncology. She is known for her strategic vision and ability to build high-performing teams.
Track Record: Under Mina Kim's leadership, Acelyrin has advanced its lead product candidate, izokibep, into Phase 3 clinical trials for multiple indications. She has also overseen the expansion of the company's pipeline through strategic acquisitions and internal development programs. Her focus on execution and value creation has positioned Acelyrin as a promising player in the biopharmaceutical industry. She manages 83 employees.
What Investors Ask About Acelyrin, Inc. (SLRN) — Healthcare
What does Acelyrin, Inc. do?
Acelyrin, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative medicines for immune-mediated diseases. Their lead product candidate, izokibep, is a small protein therapeutic designed to inhibit IL-17A with high potency. It is currently in Phase 3 clinical trials for the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as Phase 2 clinical trials for Axial Spondyloarthritis. The company also has other pipeline assets in development, including lonigutamab for thyroid eye disease and SLRN-517 for chronic urticaria. Acelyrin aims to address unmet medical needs in immunology through innovative therapies.
What do analysts say about SLRN stock?
Analyst coverage of Acelyrin, Inc. is still developing, given its status as a relatively new clinical-stage biopharmaceutical company. Current sentiment reflects a cautious optimism, acknowledging the potential of izokibep and the company's pipeline. Valuation metrics are primarily based on future revenue projections and the probability of success for its clinical programs. Investors should closely monitor clinical trial results and regulatory milestones, as these will significantly impact the company's valuation. The company's financial position and cash runway are also key considerations for analysts.
What are the main risks for SLRN?
The primary risks for Acelyrin, Inc. are inherent in the biopharmaceutical industry and include clinical trial failures or delays, regulatory hurdles, and competition from established players. Specifically, the success of Acelyrin hinges on the positive outcome of its Phase 3 trials for izokibep. Failure to demonstrate efficacy or safety in these trials could significantly impact the company's value. Additionally, the company faces competition from existing therapies and potential biosimilars. Acelyrin's financial position and ability to secure additional funding are also critical risks, given its high cash burn rate and lack of current profitability.
What are the key growth opportunities for SLRN in healthcare?
Acelyrin, Inc.'s key growth opportunities lie in the successful development and commercialization of its pipeline assets, particularly izokibep. Expansion into new therapeutic areas beyond the current indications, such as other IL-17A-mediated diseases, represents a significant growth driver. Strategic partnerships with larger pharmaceutical companies could also accelerate commercialization and expand market reach. Additionally, advancements in drug delivery technologies could improve the efficacy and patient convenience of its therapies, further enhancing their market potential. Successful execution of these strategies will be crucial for Acelyrin's long-term growth in the healthcare sector.
How does Acelyrin, Inc. plan to compete with larger pharmaceutical companies in the immunology space?
Acelyrin, Inc. plans to compete with larger pharmaceutical companies in the immunology space by focusing on developing highly targeted and differentiated therapies. Their lead product candidate, izokibep, is designed to inhibit IL-17A with high potency, potentially offering superior efficacy and safety compared to existing treatments. The company's strategy involves a combination of internal development and strategic acquisitions to build a robust pipeline of innovative therapies. Additionally, Acelyrin aims to leverage its expertise in immunology and drug development to identify and address unmet medical needs in specific patient populations, creating a competitive advantage in niche markets.
What are the key factors to evaluate for SLRN?
Acelyrin, Inc. (SLRN) currently holds an AI score of 45/100, indicating low score. Key strength: Promising lead product candidate (izokibep) in Phase 3 trials. Primary risk to monitor: Clinical trial failures or delays for izokibep or other pipeline assets. This is not financial advice.
How frequently does SLRN data refresh on this page?
SLRN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SLRN's recent stock price performance?
Recent price movement in Acelyrin, Inc. (SLRN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Promising lead product candidate (izokibep) in Phase 3 trials. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Financial projections are based on assumptions and estimates.